Maurizio Botta, LDS CEO, gives an interview on a popular television programme in Italy, dedicated to health and welfare.
Maurizio talks about the project on DDX3 inhibitors as antiviral agents active against HIV and Hepatitis C, among the others.
Maurizio’s research group together with the Molecular Genetics Institute of CNR in Pavia, identified the first molecules targeting DDX3, a human protein involved in the replication of many viral pathogens. During its interview, Maurizio outlines the innovative strategy which underpins the research project on DDX3 inhibitors, and recalls the history of this exciting discovery which mainly involved Italian research groups.
LDS is now taking part to the development of these broad spectrum antiviral agents thanks to its expertise and competences in discovery and development.
The show aired on 23th May 2016.